Genetic Determinants of the Hypokalemic and Hyperglycemic Effect of Albuterol Inhalation

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

150 participants

Study Classification

INTERVENTIONAL

Study Start Date

2002-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Several studies have indicated that albuterol administered either intravenously or by inhalation can significantly reduce plasma potassium concentration in patients suffering from chronic renal failure.In conjunction with the decrease in potassium concentration a modest rise in glucose concentration is usually noted. These metabolic effects are characterized by rapid onset occurring as early as 3-5 minutes following salbutamol administration and lasting for at least 1 hour.

The role played by ß2AR polymorphisms in determining the bronchial and vascular response to ß2AR agonist drugs, have been confirmed by several studies.

The purpose of the present study is to examine possible causal relationships between genetically based alteration in the structure of ß2AR and the metabolic effects of inhaled albuterol.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Levalbuterol Compared to Albuterol Regarding Cardiac Side Effects and Potassium Lowering Effects.

NCT05173584

Hyperkalemia

UNKNOWN PHASE4

Tissue K+ in Primary Hyperaldosteronism

NCT04251780

Primary Hyperaldosteronism Electrolyte Disturbance

COMPLETED

Glycyrrhetinic Acid-Effect on Serum Potassium and Insulin Resistance in Dialysis Patients

NCT00384384

End Stage Renal Disease

COMPLETED PHASE2

Spironolactone to Decrease Potassium Wasting in Hypercalciurics on Thiazides Diuretics

NCT00276289

Idiopathic Hypercalciuria Hypokalemia Caused by Thiazide Diuretics

COMPLETED NA

Hyperkalaemia Prevalence, Recurrence and Treatment in Haemodialysis

NCT04799067

Hyperkalemia Hemodialysis Water-Electrolyte Imbalance

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hyperkalemia Chronic Renal Failure

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Albuterol (1,200 μg) through metered-dose inhaler

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* patients regularly attending the nephrological clinic or the dialysis unit
* persistent potassium concentration above 5 mEq/L

Exclusion Criteria

1. Patients suffering from active ischemic heart disease
2. Patient with a recent history of arrhythmia
3. Patients treated regularly with ß blockers
4. Patients treated regularly with salbutamol or other ß2AR agonists
5. Patients suffering from persistent tachycardia (pulse \> 100 beats/min)
6. Patients who are hemodynamically unstable
7. Patients suffering from any acute illness

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No